Neurodegeneration: From Neurocentric to System-Wide Perspectives (N3)
June 22-25, 2026  | Fairmont Chateau Whistler, Whistler, BC, Canada
Julia TCW, Christian Haass and Emma Mead
Scholarship Deadline: Feb. 19, 2026 | Abstract Deadline: Jun. 2, 2026 | Early Registration Deadline: Apr. 24, 2026
* Session Chair † Invited but not yet accepted | Program current as of August 23, 2025 4 AM | For the most up-to-date details, visit https://www.keystonesymposia.org
Monday, June 22, 2026
4:00–8:00 PM Registration
6:00–8:00 PM Welcome Mixer
Tuesday, June 23, 2026
7:00–8:00 AM Breakfast
8:00–9:00 AM Welcome and Keynote Session (Joint)
  Christian Haass, Ludwig-Maximilians University Munich
Modulation of Microglial Function
 
  Astrid Iversen, University of Oxford
Genomic Risk for Neuroinflammation
 
9:00–11:15 AM Integrating Degeneration and Inflammation (Joint)
  Malú Gámez Tansey, Indiana University School of Medicine
Role of Central-Peripheral Neuroimmune Cross-Talk in Neurodegeneration
 
  Bart De Strooper, University College London
Key Inflection Points in Alzheimer’s Disease Pathogenesis
 
  Short Talk(s) Chosen from Abstracts
 
9:30–9:50 AM Coffee Break
11:15–1:00 PM Poster Setup
11:15–5:00 PM On Own for Lunch
1:00–10:00 PM Poster Viewing
2:30–4:30 PM Panel Discussion: From Research to Clinical Practice
4:30–5:00 PM Coffee Available
5:00–7:00 PM Neurodegenerative Disease Diagnostic to Therapeutics
  Yimin Zou, University of California, San Diego
Planar Cell Polarity Proteins in Synapse Degeneration
 
  Henne Holstege, Amsterdam UMC
Biomarker for Centenarians
 
  Matthias Brendel, LMU Munich
Molecular Imaging with PET for Translation towards Therapeutics
 
  Short Talk(s) Chosen from Abstracts
 
7:00–8:00 PM Social Hour with Dinner
7:30–10:00 PM Poster Session 1
Wednesday, June 24, 2026
7:00–8:00 AM Breakfast
8:00–11:00 AM Disease Overarching Mechanisms of Neurodegenerative Diseases
  Julia TCW, Boston University
Lipophagic Defect by APOE4 in AD Glia
 
  Justin Ichida, USC Keck School of Medicine
Using Patient Stem Cells to Identify Therapeutic Targets for Familial and Sporadic ALS
 
  Aaron D. Gitler, Stanford University School of Medicine
Single Cell Mechanisms of Neurodegeneration
 
  Short Talk(s) Chosen from Abstracts
 
9:00–9:20 AM Coffee Break
11:00–1:00 PM Poster Setup
11:00–5:00 PM On Own for Lunch
1:00–10:00 PM Poster Viewing
1:15–2:45 PM Perspectives: Personalized Medicine & Patient-Centered Strategies (Joint)
  Short Talk(s) Chosen from Abstracts
 
3:00–4:30 PM Career Roundtable (Joint)
4:30–5:00 PM Coffee Available
5:00–7:00 PM Myeloid-Based Disease Mechanisms for Neurodegenerative Diseases
  Donna M. Wilcock, Indiana University School of Medicine
Therapeutic Trem2 Activation Ameliorates Amyloid-beta Deposition and Improves Cognition in the 5XFAD Model of Amyloid Deposition
 
  Zhiqiang An, The University of Texas Health Science Center at Houston
Antibodies Targeting the LILRB2/TREM2 Axis in AD
 
  Marco Colonna, Washington University School of Medicine
Microglial Neurodegeneration Mechanisms
 
  Short Talk(s) Chosen from Abstracts
 
7:00–8:00 PM Social Hour with Dinner
7:30–10:00 PM Poster Session 2
Thursday, June 25, 2026
7:00–8:00 AM Breakfast
8:00–11:00 AM Drug Delivery (Joint)
  Fiona C. Elwood, Janssen R&D
Developing Drugs for CNS Disorders: Considerations for Therapies That Cross the BBB
 
  Kate Monroe, Denali Therapeutics
Human Genetics Identifies Novel Microglial Targeting Therapeutic Approaches for Alzheimer's Disease
 
  Sebastian Boland, Prevail Therapeutics, Eli Lilly
Talk Title to be Announced
 
  Christopher J. Barnum, INmune Bio Inc.
Selective Targeting of Soluble TNF to Mitigate Neuroinflammation in Neurodegenerative Diseases
 
  Short Talk(s) Chosen from Abstracts
 
9:00–9:20 AM Coffee Break
11:00–5:00 PM On Own for Lunch
2:30–4:30 PM Symposia Spotlight: Late-breaking research presentations selected from abstract submissions
  Short Talks Chosen from Abstracts
 
4:30–5:00 PM Coffee Available
5:00–6:45 PM Target-Based Therapeutics
  Emma Mead, Oxford Drug Discovery Institute
USP11 Inhibitors and tau Proteostasis
 
  Haiyan Peng, Alnylam Pharmaceuticals
The Application of RNAi Therapeutics in Neurodegenerative Diseases
 
  Marcos Costa, F. Hoffmann-La Roche Ltd
Correcting RNA Mis-Splicing in TDP-43 Proteinopathy
 
  Short Talk(s) Chosen from Abstracts
 
6:45–7:30 PM Closing Keynote Address
  Dennis J. Selkoe, Harvard Medical School
A Century of Alzheimer’s Research – Did We Finally Reach Our Goal?
 
7:30–7:45 PM Meeting Wrap-Up: Outcomes and Future Directions
7:45–8:45 PM Social Hour with Dinner
8:00–11:00 PM Entertainment
8:00–11:00 PM Cash Bar
Friday, June 26, 2026
12:00–11:59 PM Departure